Pay in 4 interest-free payments of $18.75 Learn more
Ships within 48 hours · Estimated delivery Jul 28 - Aug 2
In a UT7/EPO cell line
NC(N)=NC1C=CC(=CC=1)C(=O)OC1=CC2=CC=C(C=C2C=C1)C(N)=N
InChi: InChI=1S/C18H26O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h10
2010 Nov 18
Yusheng Xiong
Axitinib Catalog No.:M11394-2 In a UT7/EPO cell lineAxitinib, also known as AG013736, is an orally bioavailable tyrosine kinase inhibitor. Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platelet derived growth factor receptor (PDGF), thereby exerting an anti angiogenic effect. A xitinib has received FDA (27 January 2012), EMA (13 September 2012), MHRA (3 September 2012) and TGA (26 July 2012) approval for use as a treatment for renal cell carcinoma. Product
US$ 198.00
US$ 108.64
US$ 190.00
US$ 196.00
US$ 176.00
US$ 207.00